A new analyst report spotlights 3 more deaths, ARIA among Alzheimer's patients taking Aduhelm
A prominent Wall Street analyst is delving back into the agency’s adverse event database, identifying 3 additional deaths among patients taking the controversial Alzheimer’s drug Aduhelm — though he’s careful to add that there is no conclusive link between the drug and any deaths in this group so far.
Brian Abrahams at RBC, who’s stirred up some controversy with an initial report of a patient death back in November, also ran some numbers on the reports of ARIA seen among these patients in an effort to tease out just how dangerous this drug may be when used in the real world, as opposed to the carefully monitored clinical trials Biogen used to initially test its safety and efficacy. ARIA involves brain swelling and microbleeds that could threaten patients, though Biogen researchers have insisted that it’s a safety signal that can be monitored and treated in practice.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
